Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Primary Purpose
Venous Insufficiency
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Antistax®
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Venous Insufficiency
Eligibility Criteria
Inclusion Criteria:
- Male or female
- 18 years of age or older
- CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
- Willing and able to give written informed consent prior to participation in the study
Exclusion Criteria:
Concomitant diseases:
- Decompensated cardiac insufficiency
- Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
- Peripheral arterial disease (ankle/arm pressure index < 0.9)
- Current acute phlebitis or thrombosis
- Renal insufficiency (serum creatinine > 1.5 mg/dl)
- Liver disease (SGPT > 3x upper limit of normal)
- Other diseases: hyper- or hypocalcaemia, malignancies
- Anamnestic indications of diabetic microangiopathy or polyneuropathy
- Drug and/or alcohol abuse
- Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
- Immobility
- Avalvulia
- Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
- State after pulmonary embolism
- Recognised hypersensitivity to the trial drug ingredients
- Current florid venous ulcus
- Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
Previous treatments:
- Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
- Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
- Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
Concomitant treatment/non-drug therapy exclusion criteria:
- Other venous drugs apart from the trial medication
- Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
- Extensive use of laxatives
- Major surgery requiring full anaesthesia
Other exclusion criteria:
- Previously studied under this protocol
- Participation in another clinical trial within the previous 90 days or during the present study
- Patient is investigator, co-investigator, or study nurse in this study
- Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
- Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
- Patients in a bad general health state according to the investigator's judgement
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Antistax®
Placebo
Arm Description
1 tablet per day for 12 weeks
Outcomes
Primary Outcome Measures
Change from baseline in limb volume determination
water displacement method
Secondary Outcome Measures
Changes in limb volume determination
water displacement method
Changes in the calf circumference
in centimeters
Changes in the ankle circumference
in centimeters
Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)
Global assessment of efficacy by the investigator on a 4-point VRS
Global assessment of tolerability by the patient on a 4-point VRS
Global assessment of tolerability by the investigator on a 4-point VRS
Number of patients with adverse events
Number of patients with clinically significant changes in laboratory values
Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02191254
Brief Title
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Official Title
A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
October 2004 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Insufficiency
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
245 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Antistax®
Arm Type
Experimental
Arm Description
1 tablet per day for 12 weeks
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Antistax®
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in limb volume determination
Description
water displacement method
Time Frame
Baseline, day 84
Secondary Outcome Measure Information:
Title
Changes in limb volume determination
Description
water displacement method
Time Frame
Baseline, day 21 and day 42
Title
Changes in the calf circumference
Description
in centimeters
Time Frame
Baseline, at day 21, 42 and 84
Title
Changes in the ankle circumference
Description
in centimeters
Time Frame
Baseline, at day 21, 42, and 84
Title
Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)
Time Frame
Baseline, at day 21, 42, and 84
Title
Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)
Time Frame
day 84
Title
Global assessment of efficacy by the investigator on a 4-point VRS
Time Frame
day 84
Title
Global assessment of tolerability by the patient on a 4-point VRS
Time Frame
day 84
Title
Global assessment of tolerability by the investigator on a 4-point VRS
Time Frame
Day 84
Title
Number of patients with adverse events
Time Frame
up to 12 weeks
Title
Number of patients with clinically significant changes in laboratory values
Time Frame
Baseline, week 12
Title
Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))
Time Frame
Baseline, up to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female
18 years of age or older
CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
Willing and able to give written informed consent prior to participation in the study
Exclusion Criteria:
Concomitant diseases:
Decompensated cardiac insufficiency
Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
Peripheral arterial disease (ankle/arm pressure index < 0.9)
Current acute phlebitis or thrombosis
Renal insufficiency (serum creatinine > 1.5 mg/dl)
Liver disease (SGPT > 3x upper limit of normal)
Other diseases: hyper- or hypocalcaemia, malignancies
Anamnestic indications of diabetic microangiopathy or polyneuropathy
Drug and/or alcohol abuse
Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
Immobility
Avalvulia
Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
State after pulmonary embolism
Recognised hypersensitivity to the trial drug ingredients
Current florid venous ulcus
Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.
Previous treatments:
Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication
Concomitant treatment/non-drug therapy exclusion criteria:
Other venous drugs apart from the trial medication
Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
Extensive use of laxatives
Major surgery requiring full anaesthesia
Other exclusion criteria:
Previously studied under this protocol
Participation in another clinical trial within the previous 90 days or during the present study
Patient is investigator, co-investigator, or study nurse in this study
Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
Patients in a bad general health state according to the investigator's judgement
12. IPD Sharing Statement
Citations:
PubMed Identifier
33141449
Citation
Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, Vargas E, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020 Nov 3;11(11):CD003229. doi: 10.1002/14651858.CD003229.pub4.
Results Reference
derived
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1138/1138.4_U05-0299.pdf
Description
Related Info
Learn more about this trial
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
We'll reach out to this number within 24 hrs